Knockdown of ANXA10 inhibits proliferation and promotes apoptosis of papillary thyroid carcinoma cells by down-regulating TSG101 thereby inactivating the MAPK/ERK signaling pathway

Annexin A protein family: Focusing on the occurrence, progression and treatment of cancer

“…The members of the ANXA protein family play the opposing roles of promoting and inhibiting tumour proliferation through their participation in or activation of signalling pathways. The exceptions are ANXA5, ANXA6, ANXA10 and ANXA11, which play roles in several tumour types, while other ANXA members promote tumour cell proliferation (Grewal et al, 2010;Li et al, 2018a;Liu et al, 2019;Liu et al, 2020;Liu et al, 2021a;Zhou et al, 2021a;Zhou et al, 2021b;Gu et al, 2021;Huang et al, 2021;Ju et al, 2021;Wei and Zhu, 2021). In hepatocellular carcinoma, the overexpression of ANXA2 (Zhang et al, 2013), ANXA3 (Guo et al, 2021a), ANXA4 (Liu et al, 2017), ANXA5 (Sun et al, 2018) and ANXA11 (Liu et al, 2019) promotes proliferation because ANXA2-ANXA5 affect Wnt/β-catenin, MEK-ERK, PI3K/AKT-HIF-α and other pathways.…”

“…Similarly, in lung cancer, the overexpression of ANXA8 activates the EGFR/ AKT/mTOR signalling pathway to promote proliferation (Zhou et al, 2021a), while in thyroid cancer, increased ANXA1 promotes thyroid cancer proliferation by mediating IL-6/JAK2/STAT3 (Zhao et al, 2021). In contrast, the overexpression of the ANXA10 gene significantly inhibits HepG2 cell proliferation in vitro, and its downregulation inhibits papillary thyroid cancer proliferation; it acts directly on TSG101 by inactivating the MAPK/ERK signalling pathway (Wei and Zhu, 2021). In gastric cancer, different ANXA proteins show either proliferation promoting or inhibiting effects.…”

“…Apoptosis is an ordered and coordinated cellular process that occurs under physiological and pathological conditions (Wong, 2011). Evidence suggests that the ANXA protein family has a dual role in tumour cell apoptosis, namely, anti-apoptotic and proapoptotic activity (Figure 4) (Huang et al, 2008;Liu et al, 2012;Wei and Zhu, 2021). ANXA2 silencing significantly decreases the mRNA and protein expression of Bcl-1 and promotes apoptosis in osteosarcoma through the AKT signalling pathway and, in lung cancer, by the activity of p53 (Huang et al, 2008;Pan et al, 2018).…”

“…While ANXA10 plays a diverse role in different tumours, in hepatocellular carcinoma, the overexpression of ANXA10 significantly promotes apoptosis. Conversely, in papillary thyroid cancer, the knockdown of ANXA10 promotes apoptosis by inhibiting the MAPK/ERK signalling pathway through the downregulation of TSG101 (Liu et al, 2012;Wei and Zhu, 2021). Although studies have shown the functional diversity of ANXA proteins in apoptosis, a deeper understanding of ANXA would make an important contribution to the field of cancer treatment by enhancing apoptosis.…”

Role of annexin A family in tumorigenesis and chemoresistance of gastric cancer

“…ANXA10 is a newly identified member of the annexin A family, and hence, its physiological function in humans remains unclear. Only a few studies have been reported about ANXA10 and its varied role in different types of tumors [105]. Furthermore, ANXA10 is mapped on chromosome 4q33, while the variation of chromosome 4q was a prominent feature of hepatocellular carcinoma (HCC), which is lowly expressed in hepatoma tissues and ac ted as a tumor suppressor in HCC [106][107][108].…”